Novartis AG is the latest big pharma to turn to Alteogen Inc. to convert biologic drugs into subcutaneous (SC) formulations. Under the terms announced after Korean market hours Sept. 2, Alteogen granted Novartis, through option agreements, exclusive rights to develop and commercialize multiple products using Alteogen\u2019s ALT-B4 platform.<\/p>\n
BioWorld<\/a> Deals and M&A<\/a> Cancer<\/a> Immune<\/a> Inflammatory<\/a> Enzyme<\/a> Asia-Pacific<\/a> Europe<\/a> U.S.<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Novartis AG is the latest big pharma to turn to Alteogen Inc. to convert biologic drugs into subcutaneous…\n","protected":false},"author":2,"featured_media":124798,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[127],"tags":[60732,61001,941,61002,8086,2112,8568,19767,61004,61007,197,61003,60733,15284,61006,61005,4903,206,1078,44121,2278],"class_list":["post-124797","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novartis","tag-alt-b4","tag-alteogen-inc","tag-asia-pacific","tag-berahyaluronidase-alfa","tag-bioworld","tag-cancer","tag-deals-and-ma","tag-drug-delivery","tag-enhanze","tag-enzyme","tag-europe","tag-halozyme-inc","tag-hybrozyme","tag-immune","tag-inflammatory","tag-keytruda-qlex","tag-merck-co-inc","tag-novartis","tag-novartis-ag","tag-subcutaneous-drug-delivery","tag-u-s"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/117204721544781119","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/124797","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=124797"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/124797\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/124798"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=124797"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=124797"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=124797"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}